Gurkan Bebek1, Mohammed Orloff, Charis Eng. 1. Genomic Medicine Institute, Cleveland Clinic, 9500 Euclid Avenue, Mailstop NE-50 Cleveland, OH 44195, USA. engc@ccf.org.
Abstract
BACKGROUND: Advanced stage head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer with low survival rates. Loss-of-heterozygosity/allelic imbalance (LOH/AI) analysis has been widely used to identify genomic alterations in solid tumors and the tumor microenvironment (stroma). We hypothesize that these identified alterations can point to signaling networks functioning in HNSCC epithelial-tumor and surrounding stroma (tumor microenvironment). RESULTS: Under the assumption that genes in proximity to identified LOH/AI regions are correlated with the tumorigenic phenotype, we mined publicly available biological information to identify pathway segments (signaling proteins connected to each other in a network) and identify the role of tumor microenvironment in HNSCC. Across both neoplastic epithelial cells and the surrounding stromal cells, genetic alterations in HNSCC were successfully identified, and 75 markers were observed to have significantly different LOH/AI frequencies in these compartments (p < 0.026). We applied a network identification approach to the genes in proximity to these 75 markers in cancer epithelium and stroma in order to identify biological networks that can describe functional associations amongst these marker-associated genes. CONCLUSIONS: We verified the involvement of T-cell receptor signaling pathways in HNSCC as well as associated oncogenes such as LCK and PLCB1, and tumor suppressors such as STAT5A, PTPN6, PARK2. We identified expression levels of genes within significant LOH/AI regions specific to stroma networks that correlate with better outcome in radiation therapy. By integrating various levels of high-throughput data, we were able to precisely focus on specific proteins and genes that are germane to HNSCC.
BACKGROUND: Advanced stage head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer with low survival rates. Loss-of-heterozygosity/allelic imbalance (LOH/AI) analysis has been widely used to identify genomic alterations in solid tumors and the tumor microenvironment (stroma). We hypothesize that these identified alterations can point to signaling networks functioning in HNSCC epithelial-tumor and surrounding stroma (tumor microenvironment). RESULTS: Under the assumption that genes in proximity to identified LOH/AI regions are correlated with the tumorigenic phenotype, we mined publicly available biological information to identify pathway segments (signaling proteins connected to each other in a network) and identify the role of tumor microenvironment in HNSCC. Across both neoplastic epithelial cells and the surrounding stromal cells, genetic alterations in HNSCC were successfully identified, and 75 markers were observed to have significantly different LOH/AI frequencies in these compartments (p < 0.026). We applied a network identification approach to the genes in proximity to these 75 markers in cancer epithelium and stroma in order to identify biological networks that can describe functional associations amongst these marker-associated genes. CONCLUSIONS: We verified the involvement of T-cell receptor signaling pathways in HNSCC as well as associated oncogenes such as LCK and PLCB1, and tumor suppressors such as STAT5A, PTPN6, PARK2. We identified expression levels of genes within significant LOH/AI regions specific to stroma networks that correlate with better outcome in radiation therapy. By integrating various levels of high-throughput data, we were able to precisely focus on specific proteins and genes that are germane to HNSCC.
Authors: Eva Munck-Wikland; Per Attner; Anders Näsman; Lalle Hammerstedt; Torbjörn Ramqvist; Tina Dalianis Journal: Lakartidningen Date: 2010 Jun 30-Jul 20
Authors: Michael P Lisanti; Ubaldo E Martinez-Outschoorn; Stephanos Pavlides; Diana Whitaker-Menezes; Richard G Pestell; Anthony Howell; Federica Sotgia Journal: Cell Cycle Date: 2011-07-01 Impact factor: 4.534
Authors: Boudewijn J M Braakhuis; Maarten P Tabor; J Alain Kummer; C René Leemans; Ruud H Brakenhoff Journal: Cancer Res Date: 2003-04-15 Impact factor: 12.701
Authors: Koichi Fukino; Lei Shen; Satoshi Matsumoto; Carl D Morrison; George L Mutter; Charis Eng Journal: Cancer Res Date: 2004-10-15 Impact factor: 12.701
Authors: Dohun Pyeon; Michael A Newton; Paul F Lambert; Johan A den Boon; Srikumar Sengupta; Carmen J Marsit; Craig D Woodworth; Joseph P Connor; Thomas H Haugen; Elaine M Smith; Karl T Kelsey; Lubomir P Turek; Paul Ahlquist Journal: Cancer Res Date: 2007-05-15 Impact factor: 12.701
Authors: Robbert J C Slebos; Yajun Yi; Kim Ely; Jesse Carter; Amy Evjen; Xueqiong Zhang; Yu Shyr; Barbara M Murphy; Anthony J Cmelak; Brian B Burkey; James L Netterville; Shawn Levy; Wendell G Yarbrough; Christine H Chung Journal: Clin Cancer Res Date: 2006-02-01 Impact factor: 12.531
Authors: Sally A Amundson; Khanh T Do; Lisa C Vinikoor; R Anthony Lee; Christine A Koch-Paiz; Jaeyong Ahn; Mark Reimers; Yidong Chen; Dominic A Scudiero; John N Weinstein; Jeffrey M Trent; Michael L Bittner; Paul S Meltzer; Albert J Fornace Journal: Cancer Res Date: 2008-01-15 Impact factor: 12.701